Every material Form 8-K BIO KEY INTERNATIONAL INC has filed with the SEC since September 08, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
BIO-key stockholders approved three of four proposals at the reconvened October 2, 2026 annual meeting, including election of five directors and ratification of M&K CPAs, PLLC as auditor. The company adjourned the meeting to October 30, 2026 to give stockholders more time to vote on Proposal 4, which seeks approval for issuing up to 1,236,668 shares from warrants issued in its August 10, 2026 warrant inducement transaction.
Proposals 1 to 3 approved: five directors elected, M&K CPAs, PLLC ratified for 2026 (497,275 votes for), and non-binding executive pay approved (175,347 votes for).
Proposal 4 seeks Nasdaq Listing Rule 5635(d) approval for up to 1,236,668 shares tied to the August 10, 2026 warrant inducement; its polls remain open.
Reconvened meeting set for October 30, 2026 at 10:00 a.m. local time; 606,778 shares, about 55.8% of 1,087,360 shares entitled to vote, were present at the October 2 session.
BIO-key International entered four Exchange Agreements on September 29, 2026 with lender Streeterville Capital, LLC, converting $416,315.80 of principal from its September 30, 2025 secured note into four new promissory notes that were then exchanged for 247,805 shares of common stock. The filing says the original $1,130,000 note has now been paid in full, and the share issuance was unregistered under Section 3(a)(9) of the Securities Act, so it adds to the share count.
Exchange Agreements dated September 29, 2026 with Streeterville Capital, LLC
$416,315.80 of Original Note principal exchanged, with the Original Note described as paid in full
Issued 247,805 unregistered shares of common stock under Section 3(a)(9) of the Securities Act
BIO-key International said its 2026 Annual Meeting of Stockholders, convened September 3, 2026, lacked enough votes to approve Proposal 4, which covers issuing up to 1,236,668 shares on exercise of warrants from its August 10, 2026 warrant inducement transaction. The company adjourned the meeting to October 2, 2026, and asked stockholders who have not voted on Proposal 4 to submit a new proxy, which matters because the share issuance is needed to meet Nasdaq listing rules.
Proposal 4 would approve up to 1,236,668 shares for warrants issued in the August 10, 2026 warrant inducement transaction, for Nasdaq Listing Rule 5635(d) purposes.
The Annual Meeting will reconvene on Friday, October 2, 2026, at 10:00 a.m. local time in Holmdel, NJ.
The record date remains July 15, 2026; stockholders who have already voted and do not want to change their vote need not act.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every BIO KEY INTERNATIONAL INC filing is on SEC EDGAR ↗. 8-K briefs of other companies →